Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Teijin Pharma to Expand Overseas Marketing of Febuxostat in 117 Countries
April 12, 2012
- Taiho’s TS-1 Launched in UK, Approved in Hong Kong
April 12, 2012
- Toyota Tsusho Signs Agreement with Korean Venture to Become Sole Agent in Japan
April 12, 2012
- Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
- Takeda Pharmaceutical to Be Refunded 57.1 Bil. Yen for Transfer Pricing Taxation
April 11, 2012
- Sales Level Off for Year Ended Feb 2012 on Effects of Earthquake: Hisamitsu
April 11, 2012
- Sales of Ethical Drugs Up 8.7% in February: Crecon Report
April 10, 2012
- GSK Ties Up with Chiome for Antibody Generation Technology
April 10, 2012
- Fuso, Kaken to Jointly Market Topical Hemostatic Agent
April 10, 2012
- Ethical Drug Production in 2019 Predicted at 11 Trillion Yen: Yano Research Survey
April 10, 2012
- Anticoagulant Market to Heat Up with Lifting of Ban on Long-term Prescription of Prazaxa, Debut of New Products
April 10, 2012
- Generics Made in India to Storm Japanese Market with Overwhelming Price Advantage
April 10, 2012
- Bayer Yakuhin to Focus on 2 Prospective Blockbusters, Target 200 Billion Yen in Sales in 2013: President Guth
April 9, 2012
- US FDA Recommends Approval of Mirabegron from Astellas
April 9, 2012
- Sanofi-aventis, Alfresa Agree on Joint Development of Antiepileptic Drug
April 9, 2012
- Ohara Pharmaceutical Begins Development of Glucarpidase, Aims to File for Approval in 2014
April 9, 2012
- Eisai Establishes Aricept Director Position
April 6, 2012
- MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…